[3] Gray is also co-founder, science advisory board member (SAB) and equity holder in C4 Therapeutics, Gatekeeper, Syros, Petra, B2S, Aduro, Jengu, Allorion, Inception Therapeutics, and Soltego (board member).
C4 Therapeutics, which offered IPO in 2020, was founded based on the research of Jay Bradner, current president of Novartis Institutes for BioMedical Research (NIBR), and of Nathanael S. Gray, while he was professor at Harvard Medical School.
Before moving to Stanford University, Nathanael S. Gray created Center for Protein Degradation at Harvard Medical School with $80 million agreement with Deerfield Management venture capital firm.
[5] Gray grew up in Zambia, Yemen, India and Sudan and moved to California for high school.
[6] Nathanael Gray received his BS and PhD in organic chemistry from UC Berkeley in 1999 where he discovered purvalanol.